 |
13 Diseases |  |
52 Trials |
|
52 Trials |  |
3235 News |  |
| «12...89101112131415161718...3637» |
- Xalkori (crizotinib) / Pfizer, Alecensa (alectinib) / Roche
Alectinib after Crizotinib Failure in Patients with Advanced ALK‑Positive NSCLC: Results from the Spanish Early Access Program (Exhibit Hall - Hall B) - Jun 24, 2022 - Abstract #IASLCWCLC2022IASLC_WCLC_1106;
These findings from real-world clinical practice confirm that the prolonged PFS and OS achieved with alectinib in clinical trials can also be observed in unselected advanced ALK+ NSCLC patients with ECOG PS 2 and brain metastases, and reinforce the tolerability of alectinib in heavily pre-treated patients. Additionally, this study provides details on real-world treatment patterns following the incorporation of new ALK inhibitors into the therapeutic repertoire.
- Real-World Treatment Patterns and Impact of Comorbidity Burden on Treatment Duration for Patients with ALK+ NSCLC in the US (Exhibit Hall - Hall B) - Jun 24, 2022 - Abstract #IASLCWCLC2022IASLC_WCLC_1093;
Comorbidity is associated with increased risk of treatment discontinuation among patients receiving current first-line next generation ALK TKIs (majority alectinib). The effectiveness of additional novel therapies for 1L treatment will be evaluated in future studies.Figure.
- Idhifa (enasidenib) / BMS, Servier
Differentiation Syndrome in a Patient with Non-Small-Cell Lung Cancer Harboring IDH2 Mutation Treated with Enasidenib. (Exhibit Hall - Hall B) - Jun 24, 2022 - Abstract #IASLCWCLC2022IASLC_WCLC_1070;
IDH2 mutations are also found in subclonal populations with concurrent driver mutations such as KRAS and EGFR. Several studies in progress have suggested the potential anti-tumor activity of IDH2 inhibitors in the treatment of solid tumors.
- Tagrisso (osimertinib) / AstraZeneca, Alecensa (alectinib) / Roche
Adding Alectinib Rescues Progression on Osimertinib Due to Acquired ALK p.R1275Q Variant in EGFR p.L858R-mutated NSCLC (Exhibit Hall - Hall B) - Jun 24, 2022 - Abstract #IASLCWCLC2022IASLC_WCLC_1051;
The treatment is ongoing and current progression-free survival is now 8 months, which is the longest under the whole treatment course. Effective combination of Osimertinib and Alectinib has been reported in single cases of disseminated EGFR-mutant NSCLC becoming resistant to Osimertinib through acquired ALK-fusions.
- Alecensa (alectinib) / Roche
Liquid Biopsies as a Tool for Monitoring Patients with Metastatic ALK-positive NSCLC (Exhibit Hall - Hall B) - Jun 24, 2022 - Abstract #IASLCWCLC2022IASLC_WCLC_1025;
All patients receive standard 1st line treatment with Alectinib (Alecensa®) according to Danish lung cancer treatment guidelines...The NGS analyses is performed retrospectively on blood samples taken at 3 time points: before treatment start, at 14 days after treatment start and at clinical progression or when last blood sample before death was taken. In this way the ctDNA dynamics during treatment course is captured and we will be able to determine if liquid biopsies can be helpful in managing the targeted therapy of these patients.
- Lorbrena (lorlatinib) / Pfizer, Alecensa (alectinib) / Roche
A 28-Years Old Pregnant Woman Diagnosed as ALK-Rearrangement Lung Adenocarcinoma With Multiple Brain Metastasis - Case Report (Exhibit Hall - Hall B) - Jun 24, 2022 - Abstract #IASLCWCLC2022IASLC_WCLC_1009;
In this case report, we present significant intracranial and systemic effects of second and third-generation ALK-TKI in advanced lung adenocarcinoma. We also aim to the importance of molecular-genetic testing in young non-smokers, with lung adenocarcinoma.
- Lorbrena (lorlatinib) / Pfizer, NVL-655 / Nuvalent
Preclinical Activity of NVL-655 in a Patient-Derived NSCLC Model with Lorlatinib-Resistant ALK G1202R/T1151M Mutation (Exhibit Hall - Hall B) - Jun 24, 2022 - Abstract #IASLCWCLC2022IASLC_WCLC_1002;
The potent preclinical activity of NVL-655 suggests potential clinical utility for ALK-positive patients, including those with resistant compound mutations. The MR448re PDC and xenograft are valuable additions to the ALK therapeutic research landscape where there is limited availability of patient-derived models with lorlatinib-resistant ALK compound mutations.
- Lorbrena (lorlatinib) / Pfizer
Lorlatinib for ALK+ NSCLC Patients Pretreated with Second-Generation ALK Inhibitors: Canadian Real-World Experience (Exhibit Hall - Hall B) - Jun 24, 2022 - Abstract #IASLCWCLC2022IASLC_WCLC_989;
With median follow-up of 7.3 months, lorlatinib median time-to-discontinuation has not been reached. The interim findings indicate QoL was maintained among patients receiving lorlatinib.
- Plasma-based Molecular Profiling to Guide Treatment Decisions in Patients with Advanced NSCLC and Limited Tissue Biopsy (Exhibit Hall - Hall B) - Jun 24, 2022 - Abstract #IASLCWCLC2022IASLC_WCLC_978;
P2, P2/3
With the increasing number of targeted therapies developed for molecularly-driven NSCLC, genomic profiling of all patients with advanced adenocarcinoma is crucial. When there is not enough tissue for molecular testing, plasma-based NGS can guide first-line treatment decisions in metastatic NSCLC and increase access to targeted therapy, which may lead to prolonged survival.
- Lorbrena (lorlatinib) / Pfizer, Xalkori (crizotinib) / Pfizer, Alecensa (alectinib) / Roche
Progression Pattern, Resistance Mechanism and Subsequent Therapy for ALK Positive NSCLC in the Era of Second—Generation ALK—TKIs (Exhibit Hall - Hall B) - Jun 24, 2022 - Abstract #IASLCWCLC2022IASLC_WCLC_964;
In the era of second-generation ALK-TKIs, rebiopsy which could be beneficial to establish clinical regimens and estimate the effectiveness of subsequent treatments should be highly paid attention to. Patients should not lose the chance of chemotherapy which is still an important strategy especially for patients insensitive to targeted therapy.
- Alecensa (alectinib) / Roche
The Impact of CGP on the Decision-making Process in ALK+ aNSCLC After Failure of 2nd/3rd-Generation ALK TKIs (Exhibit Hall - Hall B) - Jun 24, 2022 - Abstract #IASLCWCLC2022IASLC_WCLC_962;
In 20 eligible patients (median [m]age 63 years [range, 40-89], females 75%, adenocarcinoma 100%, failure of alectinib 90%, FoundationOne Liquid CDx 80%), CGP has altered NLST recommendation in 30% of cases (Figure 2)... CGP has a significant impact on the decision-making process in ALK-rearranged aNSCLC following progression on 2nd/3rd-generation ALK TKIs.
- Lorbrena (lorlatinib) / Pfizer, Alunbrig (brigatinib) / Takeda, Alecensa (alectinib) / Roche
Real-World Data on the Side Effects of Alectinib, Brigatinib and Lorlatinib (Exhibit Hall - Hall B) - Jun 24, 2022 - Abstract #IASLCWCLC2022IASLC_WCLC_961;
Their frequency is substantial. It is important that patients are well-informed of possible side effects in order to contribute to the management of ALK Positive lung cancer.
- Lorbrena (lorlatinib) / Pfizer, Xalkori (crizotinib) / Pfizer, Alecensa (alectinib) / Roche
Efficacy, Safety and Treatment Courses for Patients with ALK Oncogene Positive NSCLC; Retrospective Data in Single Institute (Exhibit Hall - Hall B) - Jun 24, 2022 - Abstract #IASLCWCLC2022IASLC_WCLC_960;
Patients with brain metastasis are likely to take the treatment measure of ALK-TKIs sequence. ALK-TKIs provide promising treatment outcome for patients with brain metastasis.
- Alunbrig (brigatinib) / Takeda, Alecensa (alectinib) / Roche
Integrated Efficacy and Safety of Brigatinib Following Alectinib Treatment in the ALTA-2 and J-ALTA Studies (Hall C7) - Jun 24, 2022 - Abstract #IASLCWCLC2022IASLC_WCLC_743;
P2
Brigatinib treatment demonstrated clinically meaningful efficacy in this integrated analysis of patients with advanced or metastatic ALK+ NSCLC who progressed on prior alectinib in the ALTA-2 or J-ALTA trials. Safety results were consistent with the known profile for brigatinib, with no new safety findings observed.
- Lorbrena (lorlatinib) / Pfizer, Alunbrig (brigatinib) / Takeda, Alecensa (alectinib) / Roche
Novel Human-derived EML4-ALK Fusion cell lines identify ribonucleotide reductase RRM2 as a Target of Activated ALK in NSCLC (Exhibit Hall - Hall B) - Jun 24, 2022 - Abstract #IASLCWCLC2022IASLC_WCLC_590;
These patient-derived cell lines exhibit differential sensitivity to ALK TKIs, such as lorlatinib, brigatinib and alectinib, with EML4-ALK variant 3 containing cell lines exhibiting an increased sensitivity to lorlatinib and brigatinib as compared to alectinib. In conclusion, we have identified and characterized three novel EML4-ALK-positive NSCLC cell lines and identified RRM2 as a novel dependency gene that is a promising target for synergistic drug combinations with ALK TKIs in ALK-positive NSCLC.
- Xalkori (crizotinib) / Pfizer, Zykadia (ceritinib) / Novartis, Alecensa (alectinib) / Roche
A Systematic Review (SR) of Cost-effectiveness Analysis (CEA) of ALK Inhibitors (iALK) in Advance Non-small Cell Lung Cancer (NSCLC) (Exhibit Hall - Hall B) - Jun 24, 2022 - Abstract #IASLCWCLC2022IASLC_WCLC_544;
Setting thresholds and negotiate drug prices should be prioritized to improve patients access to innovative This review showed how the cost-effectiveness thresholds varied among countries and provided an overview of the available cost-effectiveness findings for stakeholders. Setting thresholds and negotiate drug prices should be prioritized to improve patients access to innovative drugs, as iALK, in timely manner.
- | Xalkori (crizotinib) / Pfizer, Alecensa (alectinib) / Roche
Journal: Alectinib after failure to crizotinib in patients with ALK-positive non-small cell lung cancer: results from the Spanish early access program. (Pubmed Central) - Jun 22, 2022
Over 40% of patients received some treatment after alectinib, most frequently lorlatinib (65.2%) and brigatinib (32.6%). This study provides information on real-world treatment patterns and confirms the tolerability and prolonged PFS and OS observed with alectinib in clinical trials, in unselected pretreated patients with advanced ALK+ NSCLC.
- |||| Zykadia (ceritinib) / Novartis, Alecensa (alectinib) / Roche
Clinical, Real-world evidence: We also recently added another layer 👉🏼 added trial data + real world data 👉🏼Assessment of Alectinib vs Ceritinib in ALK-Positive NSCLC in Phase 2 Trials and Real-world Data https://t.co/gffGjAk5ed via @JAMANetworkOpen part of @JAMANetwork (Twitter) - Jun 19, 2022
- ||| Alecensa (alectinib) / Roche
Excellent writeup. Made it much clearer. I was familiar with the Roche work with alectinib but it hadn't registered how it had been accomplished. Incredible amount of potential here. Now to bring the government regulators on board. 1/2 (Twitter) - Jun 19, 2022
- | Alecensa (alectinib) / Roche
Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Metastases: A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors (clinicaltrials.gov) - Jun 14, 2022
P2, N=1, Terminated, Sponsor: Hoffmann-La Roche
This study provides information on real-world treatment patterns and confirms the tolerability and prolonged PFS and OS observed with alectinib in clinical trials, in unselected pretreated patients with advanced ALK+ NSCLC. N=50 --> 1 | Trial completion date: Dec 2025 --> May 2022 | Recruiting --> Terminated | Trial primary completion date: Aug 2025 --> May 2022; The data from this study is no longer needed.
- | Alecensa (alectinib) / Roche
Journal: Early Development of Ubiquitous Acanthocytosis and Extravascular Hemolysis in Lung Cancer Patients Receiving Alectinib. (Pubmed Central) - Jun 11, 2022
Frank hemolytic anemia is rare, but mild subclinical hemolysis is very frequent and poses differential-diagnostic problems. Alectinib can be continued under the regular control of hemolysis parameters, but the risk of long-term complications, such as cholelithiasis due to increased serum bilirubin in most patients, remains unclear at present.
- || Alunbrig (brigatinib) / Takeda
Review, Journal: Comparison of Efficacy and Safety of Brigatinib in First-Line Treatments for Patients with Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Systematic Review and Indirect Treatment Comparison. (Pubmed Central) - Jun 11, 2022
The incidence of grade ≥3 AEs was similar between brigatinib and other next-generation ALK inhibitors (except for alectinib), while brigatinib could significantly delay the time to worsening in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) global health status (GHS)/quality of life (QoL) vs. crizotinib (HR: 0.69, 95% CI: 0.49, 0.98). (4) Brigatinib had longer PFS compared to crizotinib and ceritinib and had comparable efficacy and safety profile with other 2nd-generation ALK inhibitors in first-line treatments for patients with ALK-positive non-small-cell lung cancer.
- || Alecensa (alectinib) / Roche
Clinical, Review, Journal: Severe Skin Toxicity Caused by Sequential Anti-PD-1 Antibody and Alectinib in Non-small-cell Lung Cancer: A Report of Two Cases and a Literature Review. (Pubmed Central) - Jun 8, 2022
Two RET-rearranged NSCLC patients experienced severe skin toxicity with alectinib after first undergoing anti-PD-1 antibody treatment with an ICI. These findings suggest that we should carefully follow patients for adverse effects of targeted drugs following ICI treatment.
- | Alunbrig (brigatinib) / Takeda, Alecensa (alectinib) / Roche
Journal: Indirect comparisons of brigatinib and alectinib for front-line ALK-positive non-small-cell lung cancer. (Pubmed Central) - Jun 8, 2022
No statistically significant differences were identified between brigatinib and alectinib in reducing the risk of disease progression overall and in patients with baseline central nervous system metastases. Brigatinib appeared similar to alectinib in reducing risk of disease progression for people with TKI-naive ALK-positive NSCLC.
- ||||| Alecensa (alectinib) / Roche
P2 data: Dont miss our poster in #ASCO22. ALEK-B: phase 2 single arm trial assessing alectinib plus bev combination as frontline treatment in advanced #ALKNSCLC. Greatful to be parte of this team effort.@ogarrieta @AndresFCardonaZ @DH_Onco @JordiRemon @maritza_rramos @lucia_zatarain (Twitter) - Jun 6, 2022
- | Alecensa (alectinib) / Roche
Journal: Identification of a EML4-ALK exon 19 fusion variant in lung adenocarcinoma and alectinib resistance. (Pubmed Central) - Jun 4, 2022
De novo resistance or refractory subtype is rare event. Herein, we identify the first case with serial next-generation sequencing (NGS) results that harboured a rare echinoderm microtubule associated protein like 4 gene (EML4) -ALK (breaking site at exon 19) fusion in a lung adenocarcinoma (LUAD) patient who acquired alectinib resistance rapidly (less than 3 months), followed by multi-drug resistance and short survival time.
- | Alecensa (alectinib) / Roche
Journal: Avascular necrosis during alectinib treatment: Case report. (Pubmed Central) - Jun 4, 2022
This is the case in the literature to develop avascular necrosis due to alectinib. We think that femoral head necrosis may develop in the patient group using alectinib and care should be taken in this regard.
- ||| Alecensa (alectinib) / Roche
Journal, Adverse events: Evaluation of Lung Toxicity Related to the Treatment With Alectinib Using a Pharmacovigilance Database. (Pubmed Central) - Jun 4, 2022
Interstitial lung disease most frequently developed within 60 days after the start of treatment. These results will be useful for monitoring adverse events associated with the use of alectinib.
- || Retrospective data, Review: Impact of Smoking on Response to the First-Line Treatment of Advanced ALK-Positive Non-Small Cell Lung Cancer: A Bayesian Network Meta-Analysis. (Pubmed Central) - Jun 4, 2022
Moreover, lorlatinib in never-smokers and low-dose alectinib in smokers could be considered optimal first-line therapy for advanced ALK-positive NSCLC. Acceptable limitations of evidence, such as study risk of bias, inconsistency, and imprecision, were present in this NMA.
- | Alecensa (alectinib) / Roche
Journal: The Impact of Comprehensive Genomic Profiling (CGP) on the Decision-Making Process in the Treatment of ALK-Rearranged Advanced Non-Small Cell Lung Cancer (aNSCLC) After Failure of 2/3-Generation ALK Tyrosine Kinase Inhibitors (TKIs). (Pubmed Central) - Jun 4, 2022
In 20 eligible patients (median [m]age 63 years [range, 40-89], females 75%, adenocarcinoma 100%, failure of alectinib 90%, FoundationOne Liquid CDx 80%), CGP has altered NLST recommendation in 30% of cases...mOS was 13.2 months (95% CI, 2.9-NR) and 13.0 months (95% CI, 6.0-NR) in groups 1 and 2, respectively (p-0.86). CGP has a significant impact on the decision-making process in ALK-rearranged aNSCLC following progression on 2/3-generation ALK TKIs.
- ||||| Alecensa (alectinib) / Roche
Another brilliant talk on management of #lungcancer #ASCO2022 “Many Alk inhibitors are ROS1 inhibitors, not interchangeable, alectinib does not target ROS1, that would be a wrong answer” @JustinGainor @CoreyLangerMD @HwakeleeMD @LuisPaz_Ares Jared Weiss & Helena Yu (Twitter) - Jun 3, 2022
- Alecensa (alectinib) / Roche
Intramedullary spinal high grade glioma with ALK fusion and excellent response to targeted treatment with alectinib: case report . (Poster Exhibition) - Jun 2, 2022 - Abstract #ISPNO2022ISPNO_889;
- Alecensa (alectinib) / Roche
Intramedullary spinal high grade glioma with ALK fusion and excellent response to targeted treatment with alectinib: case report . (Poster Exhibition) - Jun 2, 2022 - Abstract #ISPNO2022ISPNO_632;
- || Alecensa (alectinib) / Roche
Review, Journal, Companion diagnostic: A Systematic Review of Companion Diagnostic Tests by Immunohistochemistry for the Screening of Alectinib-Treated Patients in ALK-Positive Non-Small Cell Lung Cancer. (Pubmed Central) - May 30, 2022
Particularly for the ORR, the odds ratio (OR) confirmed that alectinib had a lower risk rate (OR: 2.21, [1.46-3.36], p = 0.0002, I = 39%). Therefore, the companion diagnostic test (immunohistochemistry) is an effective test to determine whether to administer alectinib to ALK-positive NSCLC patients.
- || Xalkori (crizotinib) / Pfizer, Alecensa (alectinib) / Roche
Clinical, Retrospective data, Review: Crizotinib versus Alectinib for the Treatment of ALK-Positive Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. (Pubmed Central) - May 29, 2022
Therefore, the companion diagnostic test (immunohistochemistry) is an effective test to determine whether to administer alectinib to ALK-positive NSCLC patients. In both antitumor efficacy and safety, alectinib appears to be superior to crizotinib for the treatment of ALK-positive NSCLC.
- | Xalkori (crizotinib) / Pfizer, Alunbrig (brigatinib) / Takeda, Alecensa (alectinib) / Roche
Journal: Modeling the Ex Ante Clinical Real Option Value in an Innovative Therapeutic Area: ALK-Positive Non-Small-Cell Lung Cancer. (Pubmed Central) - May 29, 2022
Ex ante ROV can be a significant value consideration in therapeutic areas with high levels of expected innovation. The potential efficacy of future drugs and incremental survival with alectinib at the projected time of arrival are important considerations in assessing ROV.
- | Xalkori (crizotinib) / Pfizer, Alecensa (alectinib) / Roche
Journal, HEOR, Real-world evidence: Alectinib versus crizotinib in ALK-positive advanced non-small cell lung cancer and comparison of next-generation TKIs after crizotinib failure: Real-world evidence. (Pubmed Central) - May 29, 2022
The potential efficacy of future drugs and incremental survival with alectinib at the projected time of arrival are important considerations in assessing ROV. Our results revealed alectinib had better PFS and higher intracranial efficacy compared to crizotinib in ALK-positive NSCLC, and might improve PFS by comparison with ceritinib and brigatinib after crizotinib failure.
- ||||| Enrollment change, Tumor mutational burden, Metastases: BFAST: A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - May 27, 2022
P2/3, N=1000, Recruiting, Sponsor: Hoffmann-La Roche
Our results revealed alectinib had better PFS and higher intracranial efficacy compared to crizotinib in ALK-positive NSCLC, and might improve PFS by comparison with ceritinib and brigatinib after crizotinib failure. N=700 --> 1000
- | Alunbrig (brigatinib) / Takeda
Journal: Strengths and pitfalls of brigatinib in non-small cell lung cancer patients' management. (Pubmed Central) - May 24, 2022
Through a spurious exercise of an indirect comparison with other available 2G ALKi, we tent to summarize the required knowledge to properly choose the best drug at the right time. Furthermore, we reviewed available data on molecular resistance mechanisms and putative therapeutic applications in other contexts, such as ROS1+ NSCLC patients or EGFR+ ones progressing to osimertinib.
- | Enrollment change, Metastases: MegaMOST: A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/characteristics in Advanced / Metastatic Tumors. (clinicaltrials.gov) - May 20, 2022
P2, N=375, Recruiting, Sponsor: Centre Leon Berard
Furthermore, we reviewed available data on molecular resistance mechanisms and putative therapeutic applications in other contexts, such as ROS1+ NSCLC patients or EGFR+ ones progressing to osimertinib. N=100 --> 375
- || Xalkori (crizotinib) / Pfizer, Alecensa (alectinib) / Roche
Concordance between #ALK IHC and plasma testing in #JTOCRR. Samples from the phase III ALEX trial. 71% positive percent agreement between IHC and plasma. Alectinib with superior PFS over crizotinib in the plasma ALK-positive population. https://t.co/mwBEAIzspX (Twitter) - May 20, 2022
- | Alecensa (alectinib) / Roche
Congrats, Stephen! Prayers that the Lolatinib works at least as long as the Alectinib. 🙏🤞🙏 (Twitter) - May 20, 2022
- ||| Alecensa (alectinib) / Roche
Dr. Ross Camidge briefly touched upon this in a discussion with @DrNeilLove (“NSCLC w/ an actionable target beyond EGFR”). Would lean towards trying Alectinib. (Twitter) - May 16, 2022
- ||| Alecensa (alectinib) / Roche
Use Alectinib Best tolerated Alk Inhibitor (Twitter) - May 16, 2022
- ||||| Alecensa (alectinib) / Roche
Clinical: Really interesting case. We had some success with alectinib in a MSS, ALK-CAD translocated colon cancer patient. We were able to get the alectinib from Genentech's off-label program. https://t.co/YTPSb6nAzj (Twitter) - May 16, 2022
- |||| Alecensa (alectinib) / Roche
Clinical: The only parallel experience I have is a complete block of approval for alectinib despite appeals for an ALK fusion positive cholangiocarcinoma patient of mine. I'm trying to get it from the company 🙏 (Twitter) - May 16, 2022
- |||| Clinical, Next-generation sequencing: Shout out to my fellow #GIonc crew. Have a young Burmese patient with EMLA-ALK fusion mutation via NGS in metastatic #crcsm, progressing on 2nd line FOLFOXIRI. Very scant data in alectinib in this setting. Anyone with clinical experience? @pashtoonkasi @marklewismd @doctorC369 (Twitter) - May 16, 2022
- |||| Lorbrena (lorlatinib) / Pfizer, Alunbrig (brigatinib) / Takeda, Alecensa (alectinib) / Roche
Clinical: Dr. @TonyMok9 discusses 1L #ALK therapy at #RomeLung22 with three excellent options: alectinib, brigatinib, lorlatinib. Which is the winner? Contrasting study design, PFS and OS results, CNS efficacy. Great discussion - a must-see speaker, always. (Twitter) - May 16, 2022
- || Xalkori (crizotinib) / Pfizer, Zykadia (ceritinib) / Novartis, Alecensa (alectinib) / Roche
Review, Journal, IO biomarker: Role of STK11 in ALK-positive non-small cell lung cancer. (Pubmed Central) - May 10, 2022
Therefore, the main purpose of this review was to summarize the role of STK11 in ALK-positive NSCLC. The present review also summarizes the treatment and drug resistance studies in ALK-positive NSCLC and the current status of STK11 research in NSCLC.